GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

patritumab deruxtecan   Click here for help

GtoPdb Ligand ID: 14121

Synonyms: HER3-DXd | MK-1022 | U3-1402
Immunopharmacology Ligand
Compound class: Antibody
Comment: Patritumab deruxtecan (MK-1022; HER3-DXd) is an anti-Erb-B2 receptor tyrosine kinase 3 (ERBB3; HER3) antibody-drug conjugate. The conjugate is a camptothecin derivative that inhibits topoisomerase I activity to kill tumour cells [5]. HER3 is a key dimerisation partner for HER receptors. Antibody binding induces rapid receptor internalisation and inhibits HER signalling.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
No information available.
Summary of Clinical Use Click here for help
Patritumab deruxtecan (MK-1022; HER3-DXd) was advanced to clinical evaluations in advanced solid tumours, in particular for EGFR-mutant NSCLC. The unconjugated monoclonal (U3-1287) has also been extensively studied for clinical efficacy in lung, head and neck and breast cancers [4].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT06596694 Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02) Phase 1/Phase 2 Interventional Merck Sharp & Dohme LLC
NCT07060807 A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016) Phase 3 Interventional Merck Sharp & Dohme LLC
NCT05338970 HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy Phase 3 Interventional Daiichi Sankyo
NCT00000189 Gepirone vs Placebo in Treatment of Cocaine Dependence - 3 Phase 2 Interventional University of Pennsylvania 3
NCT03260491 U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer Phase 1 Interventional Daiichi Sankyo 5
NCT05865990 HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease Phase 2 Interventional MedSIR 3